Summit’s lung cancer treatment has wowed researchers. The CEO behind it is a living challenge to the assumptions of many in biotech.
Relay is planning a late-stage trial comparing its breast cancer drug to a rival treatment from AstraZeneca.
“I see these results as important, but preliminary,” Chief Medical Officer Eliav Barr told STAT, reacting to a Phase 3 clinical trial involving ivonescimab.
San Diego-based Candid Therapeutics, helmed by former RayzeBio CEO Ken Song, will test two promising autoimmune drug candidates.
